The EU Commission raises the stakes by issuing a Statement of Objections against a healthcare company in which it threatens to adopt interim measures to prevent potentially irreparable damage to competition (Illumina / GRAIL)

KEYWORDS
Reference

EU Commission, Illumina / GRAIL, Press release, 20 September 2021

In September 2021, the European Commission (the Commission) announced that it would open an investigation to determine whether Illumina’s decision to acquire Grail pending its review of that transaction under Regulation 139/2004 on the control of concentrations between

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Van Bael & Bellis (Brussels)
    France 38 contributions 20731 visits
  • Van Bael & Bellis (Brussels)
    United Kingdom 145 contributions 50382 visits
  • Van Bael & Bellis (Brussels)
    Belgium 47 contributions 23676 visits
  • Van Bael & Bellis (Brussels)
    Belgium 46 contributions 22762 visits

Quotation

Michael Clancy, Peter L'Ecluse, Catherine Longeval, Koen T'Syen, The EU Commission raises the stakes by issuing a Statement of Objections against a healthcare company in which it threatens to adopt interim measures to prevent potentially irreparable damage to competition (Illumina / GRAIL), 20 September 2021, e-Competitions September 2021, Art. N° 102430

Visites 490

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues